{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T08:11:55Z","timestamp":1788595915793,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.autrev.2026.104173","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:08:30Z","timestamp":1788278910000},"page":"104173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacological personalization of JAK inhibitors in rheumatoid arthritis: A multi-omics and AI\u2013based scoping review and evidence-gap map"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8897-0912","authenticated-orcid":false,"given":"Tatiana","family":"Bobkova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artem","family":"Bobkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2026.104173_bb0005","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S2665-9913(23)00211-4","article-title":"Global, regional, and national burden of rheumatoid arthritis, 1990\u20132020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021","volume":"5","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2026.104173_bb0010","first-page":"591","article-title":"Global epidemiology of rheumatoid arthritis","volume":"18","author":"Finckh","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2026.104173_bb0015","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104173_bb0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104173_bb0025","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2026.104173_bb0030","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","article-title":"Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response","volume":"78","author":"Fleischmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104173_bb0035","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"ORAL surveillance investigators. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104173_bb0040","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104173_bb0045","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41584-022-00845-w","article-title":"Precision medicine: the precision gap in rheumatic disease","volume":"18","author":"Lin","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2026.104173_bb0050","article-title":"Artificial intelligence and multi-omics in pharmacogenomics: a new era of precision medicine","volume":"3","author":"Zack","year":"2025","journal-title":"Mayo Clin Proc Digit Health"},{"key":"10.1016\/j.autrev.2026.104173_bb0055","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.11761","article-title":"Whole-blood RNA sequencing profiling of patients with rheumatoid arthritis treated with tofacitinib","volume":"7","author":"Bellocchi","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.autrev.2026.104173_bb0060","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s10067-024-06931-6","article-title":"Revealing the changes in signaling pathways caused by tofacitinib in patients with rheumatoid arthritis through RNA sequencing and the correlation with clinical parameters","volume":"43","author":"Lu","year":"2024","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2026.104173_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.07.091","article-title":"Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes","volume":"28","author":"Lewis","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.autrev.2026.104173_bb0070","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41591-022-01789-0","article-title":"Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial","volume":"28","author":"Rivellese","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2026.104173_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/ph18081152","article-title":"Pharmacological inhibition of the PI3K\/AKT\/mTOR pathway in rheumatoid arthritis synoviocytes: a systematic review and meta-analysis (preclinical)","volume":"18","author":"Bobkova","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.autrev.2026.104173_bb0080","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00296-025-05825-3","article-title":"Artificial intelligence to predict treatment response in rheumatoid arthritis and spondyloarthritis: a scoping review","volume":"45","author":"Benavent","year":"2025","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2026.104173_bb0085","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-082505","article-title":"PROBAST+AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods","volume":"388","author":"Moons","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2026.104173_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152501","article-title":"Machine learning in the prediction of treatment response in rheumatoid arthritis: a systematic review","volume":"68","author":"Mendoza-Pinto","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104173_bb0095","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11926-025-01193-w","article-title":"Emerging artificial intelligence innovations in rheumatoid arthritis and challenges to clinical adoption","volume":"27","author":"Gilvaz","year":"2025","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2026.104173_bb0100","series-title":"JBI Manual for Evidence Synthesis","year":"2024"},{"key":"10.1016\/j.autrev.2026.104173_bb0105","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2026.104173_bb0110","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS peer review of electronic search strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.autrev.2026.104173_bb0115","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2026.104173_bb0120","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2026.104173_bb0125","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/acr2.11630","article-title":"Anti-peptidylarginine deiminase 4 autoantibodies and disease duration as predictors of treatment response in rheumatoid arthritis","volume":"6","author":"Cappelli","year":"2024","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.autrev.2026.104173_bb0130","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s41927-020-00153-4","article-title":"Ultrasound and multi-biomarker disease activity score for assessing and predicting clinical response to tofacitinib treatment in patients with rheumatoid arthritis","volume":"4","author":"Razmjou","year":"2020","journal-title":"BMC Rheumatol"},{"issue":"Suppl. 9","key":"10.1016\/j.autrev.2026.104173_bb0135","article-title":"Uncovering common and distinctive molecular profiles between early and stablished rheumatoid arthritis through integrative multi-omics analysis and its association with disease status and clinical response [abstract]","volume":"76","author":"S\u00e1nchez Pareja","year":"2024","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104173_bb0140","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13075-024-03376-9","article-title":"Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib","volume":"26","author":"Hetland","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2026.104173_bb0145","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/apm.13341","article-title":"Predicting the clinical efficacy of JAK inhibitor treatment for patients with rheumatoid arthritis based on Fas+ T cell subsets","volume":"131","author":"Lui","year":"2023","journal-title":"APMIS"},{"key":"10.1016\/j.autrev.2026.104173_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.839015","article-title":"The potential of gut microbiota metabolic capability to detect drug response in rheumatoid arthritis patients","volume":"13","author":"Han","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.autrev.2026.104173_bb0155","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/art.41622","article-title":"The pretreatment gut microbiome is associated with lack of response to methotrexate in new-onset rheumatoid arthritis","volume":"73","author":"Artacho","year":"2021","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104173_bb0160","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-021-03169-7","article-title":"Serum metabolomic and lipidomic profiling identifies diagnostic biomarkers for seropositive and seronegative rheumatoid arthritis patients","volume":"19","author":"Luan","year":"2021","journal-title":"J Transl Med"},{"key":"10.1016\/j.autrev.2026.104173_bb0165","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13075-025-03596-7","article-title":"Serum tryptophan-kynurenine metabolites served as biomarkers of disease activity in rheumatoid arthritis and linked to immune imbalance","volume":"27","author":"Wu","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2026.104173_bb0170","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13075-023-03049-z","article-title":"Multi-omics profiling reveals potential alterations in rheumatoid arthritis with different disease activity levels","volume":"25","author":"Chen","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2026.104173_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1399856","article-title":"Integrated analysis of single-cell RNA-seq, bulk RNA-seq, Mendelian randomization, and eQTL reveals T cell-related nomogram model and subtype classification in rheumatoid arthritis","volume":"15","author":"Ding","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104173_bb0180","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/ard-2022-223645","article-title":"Immunomics analysis of rheumatoid arthritis identified precursor dendritic cells as a key cell subset of treatment resistance","volume":"82","author":"Yamada","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104173_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11080785","article-title":"Inference of an integrative, executable network for rheumatoid arthritis combining data-driven machine learning approaches and a state-of-the-art mechanistic disease map","volume":"11","author":"Miagoux","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.autrev.2026.104173_bb0190","first-page":"93","article-title":"RNAcare: integrating clinical data with transcriptomic evidence using rheumatoid arthritis as a case study","volume":"18","author":"Tang","year":"2025","journal-title":"BMC Med Genet"},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2026.104173_bb0195","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1136\/annrheumdis-2019-eular.5049","article-title":"AB0234 an integrated proteomics and antibody analysis of the U-ACT-EARLY trial to identify markers of treatment response and disease progression in early rheumatoid arthritis [abstract]","volume":"78","author":"Brizzi","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 9","key":"10.1016\/j.autrev.2026.104173_bb0200","article-title":"Integrative multi-omic phenotyping in blood identifies molecular signatures and candidate biomarkers of ACPA-negative rheumatoid arthritis [abstract]","volume":"74","author":"Hur","year":"2022","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2026.104173_bb0205","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/annrheumdis-2024-eular.4878","article-title":"POS0130 the use of high-throughput technologies for molecular profiling in rheumatoid arthritis enables the identification of patient subgroups with distinctive disease activity and therapeutic response [abstract]","volume":"83","author":"L\u00f3pez-Pedrera","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104173_bb0210","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41580-023-00615-w","article-title":"The technological landscape and applications of single-cell multi-omics","volume":"24","author":"Baysoy","year":"2023","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.autrev.2026.104173_bb0215","article-title":"Target trial emulation: applying principles of randomised trials to observational studies","volume":"378","author":"Matthews","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2026.104173_bb0220","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41746-024-01276-5","article-title":"Addressing fairness issues in deep learning-based medical image analysis: a systematic review","volume":"7","author":"Xu","year":"2024","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.autrev.2026.104173_bb0225","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41746-023-00913-9","article-title":"Considerations for addressing bias in artificial intelligence for health equity","volume":"6","author":"Abr\u00e0moff","year":"2023","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.autrev.2026.104173_bb0230","article-title":"Telepsychiatry and artificial intelligence: a structured review of emerging approaches to accessible psychiatric care","volume":"13","author":"Bobkov","year":"2025","journal-title":"Healthcare (Basel)"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T07:36:04Z","timestamp":1788593764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226001874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1568997226001874"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104173","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological personalization of JAK inhibitors in rheumatoid arthritis: A multi-omics and AI\u2013based scoping review and evidence-gap map","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104173","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104173"}}